REVPEM
LIVE

Serial Number

79394512

Owner

Novartis AG

Attorney

MAURY M. TEPPER, III

Filing Date

Feb 6, 2024

Add to watchlist:

No watchlists yet
View on USPTO

REVPEM Trademark

Serial Number: 79394512 • Registration: 7646846

REVPEM is a trademark filed by Novartis AG on February 6, 2024. The trademark is classified under Class 5 (Pharmaceuticals), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Novartis AG (12 trademarks)

CH-4002 Basel

Entity Type: 03

Trademark Details

Filing Date

February 6, 2024

Registration Date

January 14, 2025

Published for Opposition

November 26, 2024

Goods & Services

Collection and preservation of human blood; Collection and banking services for tissue and cells, namely, collection and banking of umbilical cord tissue perivascular stem cells; medical diagnostic services; medical treatment services, namely, treatment of cardiovascular, dermatological, ophthalmic, respiratory, gastro-intestinal, autoimmune, metabolic, endocrine, hematological, skeletal, immune, digestive, muscular, genitourinary, transplantation, nephrology, oncology and nervous systems; provision of medical information and data for diagnosis and medical treatment

Anti-infectives; Anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma.

Filing History

NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Oct 10, 2025 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Sep 24, 2025 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Sep 24, 2025 OPNR
FINAL DECISION TRANSACTION PROCESSED BY IB
Aug 23, 2025 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Jul 31, 2025 FICS
FINAL DISPOSITION PROCESSED
Jul 31, 2025 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Apr 15, 2025 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jan 14, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Jan 14, 2025 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 26, 2024 NPUB
PUBLISHED FOR OPPOSITION
Nov 26, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 20, 2024 NONP
EXPARTE APPEAL TERMINATED
Oct 29, 2024 EXPT
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 29, 2024 CNSA
EX PARTE APPEAL-INSTITUTED
Oct 28, 2024 EXPI
JURISDICTION RESTORED TO EXAMINING ATTORNEY
Oct 28, 2024 JURT
EXPARTE APPEAL RECEIVED AT TTAB
Oct 28, 2024 EXAF
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 28, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 28, 2024 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Oct 28, 2024 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Oct 25, 2024 GNFN
FINAL REFUSAL E-MAILED
Oct 25, 2024 GNFR
FINAL REFUSAL WRITTEN
Oct 25, 2024 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 2, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 2, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 2, 2024 TROA
REFUSAL PROCESSED BY IB
Sep 30, 2024 RFNP
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Sep 4, 2024 RFCS
REFUSAL PROCESSED BY MPU
Sep 4, 2024 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Sep 4, 2024 RFCR
NON-FINAL ACTION WRITTEN
Sep 3, 2024 CNRT
ASSIGNED TO EXAMINER
Aug 29, 2024 DOCK
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
May 13, 2024 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
May 13, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
May 13, 2024 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
May 13, 2024 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
May 13, 2024 COAR
APPLICATION FILING RECEIPT MAILED
May 10, 2024 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 10, 2024 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
May 2, 2024 LIMI
SN ASSIGNED FOR SECT 66A APPL FROM IB
Apr 25, 2024 REPR